三諾生物(300298.SZ):第一期員工持股計劃存續期展期2年
格隆匯12月7日丨三諾生物(300298.SZ)公佈,基於目前證券市場的情況,綜合考慮公司實際發展狀況,切實發揮員工持股計劃實施的目的和激勵作用,2021年12月2日,經公司第一期員工持股計劃持有人會議審議通過,2021年12月7日,公司召開第四屆董事會第二十次會議,審議並通過《關於公司第一期員工持股計劃存續期展期的議案》,同意將公司第一期員工持股計劃存續期展期2年,即存續期延長至2024年2月9日。除上述內容外,公司第一期員工持股計劃其它內容不變。
截至公吿披露日,公司第一期員工持股計劃持有公司股票的數量為469.522萬股,佔公司總股本564,768,137股的比例為0.83%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.